I do partially agree with you here pogues. I am over the...

I do partially agree with you here pogues. I am over the continual change of direction from management but anagrelide may save us.

Why - because as iv said before we arnt landing deals because of

A - our products arnt up to scratch

B - why would a company invest in Suda if they can’t get the little things right = bad management.

So if our product arnt up to scratch but they work, angrelide has to tick far less boxes then the other products. (Doesn’t have to have fast onset, doesn’t have to be crazily great tasting and so on as they arnt selling to the public where choice is available)

They just need a formulation that actually works!

If they get it to work, then all the other company is worried about is if trials go well and then production of it, again a lot less boxes to tick as it’s not being bought by the general public.

I’m just unsure how long the trials will be dragged out and when a partner would come and help fund. That could be the killer.